top of page

Making innovative life sciences technology available for all...

Providing evidence-based and personalised health management solutions for those most in need.

Impact Biotech

With access to scientific and clinical experts, IBH can provide the most up-to-date technologies in emerging health-related fields.

IBH identifies healthcare challenges faced by those most in need and provides opportunities to make informed decisions concerning health and treatment options.

Offering the tools needed to make the best choices that will enable the highest impact on overall health and wellbeing. 

Our vision is to make innovative life sciences technologies available for all, providing evidence-based and personalised health management solutions.


“It’s all about risk assessment and risk management. Risk avoidance is not an option.

— Prof Linfa Wang


We are proud to offer cPass, the first rapid test kit for measuring neutralising antibodies against SARS-CoV-2.

cPass™ and cPass Express™ (RUO) are tests that measure the level of Neutralising Antibodies (NAb) in blood. NAb actively block the COVID-19 virus from binding to cells, providing the most accurate indication of immunity (as a correlate of protection) against the virus.

Individual Booster Requirements

Risk Stratification

IBH has distribution rights to commercialise, launch and supply cPass™ and cPass Express™ in Australia, New Zealand, South Pacific Islands, Bangladesh, Philippines and Indonesia.

Immuno-compromised and elderly

International Travel



Dean Kilby.jpeg

Chief Scientific Officer


Kate Glennon.jpeg

Operations Manager

Our Partners

Deakin Uni.png
Bridge Impact Cap.png

Partner with IBH on Global Projects

IBH identifies fundamental impact technologies in health and life sciences.

If you have an innovative technology you’re looking to commercialise or a research study/clinical trial that would benefit from our technologies, please contact us to discuss mutually beneficial partnership opportunities.

bottom of page